Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
BACKGROUND
Proton pump inhibitor (PPI) medications have been inconsistently shown to be associated with osteoporotic fractures. We examined the association of PPI use with bone outcomes (fracture, bone mineral density [BMD]).


METHODS
This prospective analysis included 161 806 postmenopausal women 50 to 79 years old, without history of hip fracture, enrolled in the Women's Health Initiative (WHI) Observational Study and Clinical Trials with a mean (SD) follow-up of 7.8 (1.6) years. Analyses were conducted for 130 487 women with complete information. Medication information was taken directly from drug containers during in-person interviews (baseline, year 3). The main outcome measures were self-reported fractures (hip [adjudicated], clinical spine, forearm or wrist, and total fractures) and for a subsample (3 densitometry sites), 3-year change in BMD.


RESULTS
During 1 005 126 person-years of follow-up, 1500 hip fractures, 4881 forearm or wrist fractures, 2315 clinical spine fractures, and 21 247 total fractures occurred. The multivariate-adjusted hazard ratios for current PPI use were 1.00 (95% confidence interval [CI], 0.71-1.40) for hip fracture, 1.47 (95% CI, 1.18-1.82) for clinical spine fracture, 1.26 (95% CI, 1.05-1.51) for forearm or wrist fracture, and 1.25 (95% CI, 1.15-1.36) for total fractures. The BMD measurements did not vary between PPI users and nonusers at baseline. Use of PPIs was associated with only a marginal effect on 3-year BMD change at the hip (P = .05) but not at other sites.


CONCLUSIONS
Use of PPIs was not associated with hip fractures but was modestly associated with clinical spine, forearm or wrist, and total fractures.
Gray
Shelly L
SL
School of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195, USA. slgray@u.washington.edu
LaCroix
Andrea Z
AZ
Larson
Joseph
J
Robbins
John
J
Cauley
Jane A
JA
Manson
JoAnn E
JE
Chen
Zhao
Z
D000368:Aged; D015519:Bone Density / Q000187:drug effects; D005260:Female; D005598:Fractures, Spontaneous / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D010024:Osteoporosis / Q000139:chemically induced* / Q000453:epidemiology; D017698:Postmenopause; D016016:Proportional Hazards Models; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000009:adverse effects*; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D054328:Proton Pump Inhibitors
Calcif Tissue Int. 1986 Feb;38(2):123-5
3006888
Pharmacotherapy. 2008 Aug;28(8):951-9
18657011
Curr Pharm Des. 2002;8(23):2033-48
12171517
Am J Epidemiol. 1997 Nov 15;146(10):856-69
9384206
JAMA. 2006 Dec 27;296(24):2947-53
17190895
Menopause. 2004 May-Jun;11(3):264-74
15167305
Am J Med. 2005 Jul;118(7):778-81
15989913
Artif Organs. 1998 Jul;22(7):569-73
9684693
Nephron. 2002 Jul;91(3):474-9
12119480
Control Clin Trials. 1998 Feb;19(1):61-109
9492970
Ann Epidemiol. 2003 Oct;13(9 Suppl):S107-21
14575943
Med Sci Sports Exerc. 1993 Jan;25(1):71-80
8292105
Calcif Tissue Int. 1993 Jul;53(1):21-5
8102318
Calcif Tissue Int. 2006 Aug;79(2):84-94
16927048
Med Care. 1992 Jun;30(6):473-83
1593914
J Bone Miner Res. 1991 Aug;6(8):865-8
1785376
J Clin Invest. 1984 Mar;73(3):640-7
6707197
J Am Coll Nutr. 1995 Aug;14(4):364-8
8568113
Nephrol Dial Transplant. 1995;10(8):1376-80
8538929
CMAJ. 2008 Aug 12;179(4):319-26
18695179
Calcif Tissue Int. 2008 Oct;83(4):251-9
18813868
JAMA. 2007 Nov 28;298(20):2389-98
18042916